Intrathecal therapy with monoclonal antibodies in severe progressive multiple sclerosis
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Biomarker
- Acronyms ITT-PMS; PMSIT
- 18 Nov 2016 Status changed from recruiting to completed.
- 21 Aug 2015 Planned End Date changed from 1 Nov 2014 to 1 Jun 2016, as reported by ClinicalTrials.gov record.
- 21 Aug 2015 Planned primary completion date changed from 1 Nov 2014 to 1 Jun 2016, as reported by ClinicalTrials.gov record.